This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): NS-220
Description: R1593, a nuclear receptor modulator and dioxanecarboxylic acid derivative, is a highly selective PPARa agonist.
Deal Structure: In October 2003, Roche and Nippon Shinyaku announced a strategic alliance to develop drug candidates for the treatment of blood lipid dysfunction (dyslipidemia).
Under the terms of the agreement, Roche will have exclusive rights in the U.S. and Europe to market any drug resulting from the agreement. Nippon Shinyaku will have rights to co-develop and co-market in Japan, Peoples Republic of China including Hong Kong, Republic of Korea and Taiwan. Roche will pay Nippon Shinyaku milestone payments and royalties based on product sales.
Partners: Nippon Shinyaku Co., Ltd.
Additional information available to subscribers only: